TFF Pharmaceuticals Reports Third Quarter 2021 Financial Results and Provides Business Update
November 15, 2021 16:01 ET
|
TFF Pharmaceuticals, Inc.
Positive Updates Announced for Inhaled Voriconazole and Tacrolimus Programs;Both Programs Advancing into Phase 2 Testing Continued Progress with Partnered Antiviral Programs for AUG-3387 and...
TFF Pharmaceuticals Announces Completion of Dosing of Phase 1b Study for Voriconazole Inhalation Powder in Mild to Moderate Asthma Patients
November 08, 2021 08:03 ET
|
TFF Pharmaceuticals, Inc.
Initial data from Phase 1b showed Voriconazole Inhalation Powder is Well Tolerated in Asthma Patients Data Supports Progress to Phase 2 and Inclusion of Patients with Asthma AUSTIN, Texas, Nov. ...
TFF Pharmaceuticals to Participate in the 12th Annual Jefferies London Healthcare Conference 2021
November 08, 2021 08:00 ET
|
TFF Pharmaceuticals, Inc.
AUSTIN, Texas, Nov. 08, 2021 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc. (NASDAQ: TFFP), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug...
TFF Pharmaceuticals to Hold Third Quarter 2021 Financial and Business Results Conference Call on November 15, 2021
November 05, 2021 16:05 ET
|
TFF Pharmaceuticals, Inc.
AUSTIN, Texas, Nov. 05, 2021 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc. (NASDAQ: TFFP), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug...
TFF Pharmaceuticals Receives Approval from Health Canada to Enter Human Clinical Trials for Inhaled Formulation of Niclosamide to Treat COVID-19
October 28, 2021 09:16 ET
|
TFF Pharmaceuticals, Inc.
First Patient in Phase 1 Trial to be Dosed in November with Enrollment Completion Anticipated by Early Q1 2022 Preclinical Studies of Inhaled Dry Powder Formulation of Niclosamide Showed a...
TFF Pharmaceuticals and Augmenta Bioworks Publish Positive In Vivo Data Showing Dry Powder Formulation of COVID-19 Antibody, AUG-3387, Neutralizes SARS-CoV-2 Infection and Reduces Viral Load
October 14, 2021 08:30 ET
|
TFF Pharmaceuticals, Inc.
Results published in bioRxiv Show That Delivery of Dry Powder AUG-3387 Following Viral Inoculation Led to Dose-Dependent Reduction in Lung Viral Load in Hamsters Dry Powder Formulations Show...
TFF Pharmaceuticals Announces Promising Topline Results from Phase 1 Clinical Trial of Inhaled Tacrolimus Powder and Progression Toward Phase 2 in Lung Transplantation
September 23, 2021 08:00 ET
|
TFF Pharmaceuticals, Inc.
AUSTIN, Texas, Sept. 23, 2021 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc. (NASDAQ: TFFP), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug...
TFF Pharmaceuticals to Present at 23rd H.C. Wainwright Annual Global Investment Conference
September 08, 2021 16:05 ET
|
TFF Pharmaceuticals, Inc.
AUSTIN, Texas, Sept. 08, 2021 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc. (NASDAQ: TFFP), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug...
TFF Pharmaceuticals Reports Second Quarter 2021 Financial Results and Provides Business Update
August 12, 2021 16:01 ET
|
TFF Pharmaceuticals, Inc.
Additional Data Readouts and Initiation of Pivotal Trials for Inhaled Tacrolimus and Voriconazole Programs Expected in 2H 2021 Multiple Ascending Dose (MAD) Study Demonstrates Inhaled...
TFF Pharmaceuticals to Present at the SNN Virtual Investor Conference on August 19, 2021
August 05, 2021 08:30 ET
|
TFF Pharmaceuticals, Inc.
AUSTIN, Texas, Aug. 05, 2021 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc. (NASDAQ: TFFP), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug...